HC

HUTCHMED (China) LtdLSE HUTCHMED Stock Report

Last reporting period 30 Jun, 2023

Updated 18 Sep, 2024

Last price

Market cap $B

2.855

Small

Exchange

XLON - London Stock Exchange

HCM.L Stock Analysis

HC

Uncovered

HUTCHMED (China) Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

23/100

Low score

Market cap $B

2.855

Dividend yield

Shares outstanding

864.77 B

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 2,025 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

View Section: Eyestock Rating